Samaka Rehab Monir, Hemida Aiat Shaban, Alfouly Hagar, Kora Mona A
Pathology Department, Faculty of Medicine, Minufiya University, Menoufia, Shebin El-kom, 332511, Egypt.
Diagn Pathol. 2025 May 26;20(1):64. doi: 10.1186/s13000-025-01660-z.
A follicular thyroid tumour called Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) poses crossing-over morphologic characteristics with more thyroid follicular lesions whether benign or cancerous nodules. This study focuses on analysing the expression of CD56, HBME-1, RRM2 and APLP2 IHC markers in NIFTP versus other thyroid follicular lesions and their diagnostic validity was also evaluated.
one hundred and nine thyroidectomy specimens including 31 NIFTP, 34 non-neoplastic, 34 papillary thyroid carcinoma (PTC) and 10 invasive encapsulated follicular variant papillary thyroid carcinoma (IEFVPTC) cases, were acquired between 2019 and 2022 from the Menoufia University's Faculty of Medicine's Pathology Department. Tissue microarray construction (TMA) blocks were prepared and CD56, HBME-1, RRM2 and APLP2 immunostaining were performed.
For CD56, 64.5% of NIFTP, 97.1% of the non-neoplastic group and 0% of both PTC and IEFVPTC were positive. For HBME-1, 61.3% of NIFTP, 0% of non-neoplastic, 100% of PTC and 100% of IEFVPTC were positive. For RRM2, all cases of NIFTP and the non-neoplastic group were negative, 88.2% of PTC and 100.0% of IEFVPTC were positive. For APLP2, 90.3% of NIFTP, 100% of the non-neoplastic group, 100% of PTC and 100% of IEFVPTC were positive. In differentiating NIFTP from non-neoplastic cases, the most sensitive marker was CD56 at H-score < 225 (sensitivity 95%) and the most specific was HBME-1 (specificity 100%). In various combinations, the panel of combined HBME-1 with either CD56 or APLP-2 improves their specificity (96.67% and 100% respectively) and the diagnostic accuracy (86.79 and 83.87, respectively) and therefore, combined HBME-1 and CD56 seems to be the most significant than using a single marker. In differentiation between NIFTP and PTC/IEFVPTC, the most sensitive marker was RRM2 (100% sensitivity for both groups) with the highest diagnostic accuracy (93.85% and 100%, respectively) and the most specific was CD56 (specificity 100% for both groups).
Immunohistochemical markers such as CD56, HBME-1, RRM2, and APLP2 may aid in the diagnosis of NIFTP and its distinction from other follicular lesions.
一种名为具有乳头样核特征的非侵袭性滤泡性甲状腺肿瘤(NIFTP)的滤泡性甲状腺肿瘤,与更多甲状腺滤泡性病变(无论是良性还是癌性结节)存在交叉的形态学特征。本研究着重分析NIFTP与其他甲状腺滤泡性病变中CD56、HBME-1、RRM2和APLP2免疫组化标志物的表达情况,并评估它们的诊断有效性。
2019年至2022年间,从曼努菲亚大学医学院病理科获取了109份甲状腺切除标本,包括31例NIFTP、34例非肿瘤性病变、34例乳头状甲状腺癌(PTC)和10例侵袭性包裹性滤泡变异型乳头状甲状腺癌(IEFVPTC)病例。制备了组织微阵列构建(TMA)块,并进行了CD56、HBME-1、RRM2和APLP2免疫染色。
对于CD56,NIFTP的64.5%、非肿瘤性组的97.1%以及PTC和IEFVPTC的0%呈阳性。对于HBME-1,NIFTP的61.3%、非肿瘤性组的0%、PTC的100%和IEFVPTC的100%呈阳性。对于RRM2,NIFTP和非肿瘤性组的所有病例均为阴性,PTC的88.2%和IEFVPTC的100.0%呈阳性。对于APLP2,NIFTP的90.3%、非肿瘤性组的100%、PTC的100%和IEFVPTC的100%呈阳性。在区分NIFTP与非肿瘤性病例时,最敏感的标志物是H评分<225时的CD56(敏感性95%),最特异的是HBME-1(特异性100%)。在各种组合中,HBME-1与CD56或APLP-2联合使用可提高它们的特异性(分别为96.67%和100%)和诊断准确性(分别为86.79和83.87),因此,联合使用HBME-1和CD56似乎比使用单一标志物更具意义。在区分NIFTP与PTC/IEFVPTC时,最敏感的标志物是RRM2(两组敏感性均为100%),诊断准确性最高(分别为93.85%和100%),最特异的是CD56(两组特异性均为100%)。
CD56、HBME-1、RRM2和APLP2等免疫组化标志物可能有助于NIFTP的诊断及其与其他滤泡性病变的鉴别。